parkinsonsnewstoday.com/202...
The spread of alpha-synuclein aggregates in the brain is dependent on a protein receptor called TLR2, and also a transcription factor called NF-KB, a study indicates.
Blocking these proteins — which may be done with medications inhaled through the nose — may be a useful therapeutic approach in Parkinson’s disease and other conditions characterized by alpha-synuclein aggregates, its findings suggest.
The study, “Selective targeting of the TLR2/MyD88/NF-κB pathway reduces α-synuclein spreading in vitro and in vivo,” was published in Nature Communications.
More Reason for Cautious Optimism
Enzymes to dissolve the alpha-synuclein protein build up in the brain.
Vinpocetine regulates levels of circulating TLRs in Parkinson's disease patients 2019
Feedback from a PD research scientist in the department of Clinical Neuroscience at the University of Cambridge (UK), on PASADENA Trial...
squalamine which has been shown to remove alpha synuclein from the gut and is now in clinical trials for the certain symptoms associated wit
